Source: BioPortfolio

Hengrui Therapeutics: Jiangsu Hengrui Leads $100 Million Investment in US SpinOff

Hengrui Therapeutics Inc. a New Jersey offshoot of Jiangsu Hengrui Medicine raised $100 million in initial funding from HR Bio Holdings Limited a JV formed by Jiangsu Hengrui and an unnamed investment company. Initially HTI will work on US development of t...

Read full article »

Top Competitors or Alternatives

Looks like nobody has added any competitors for Hengrui Therapeutics yet.

Missing a competitor? Contribute!

Est. Annual Revenue
$6.3M
Est. Employees
28
Adam Zong's photo - President & CEO of Hengrui Therapeutics

President & CEO

Adam Zong

CEO Approval Rating

70/100

Read more